Pfizer has announced results from an analysis of 2,246 adults enrolled in its Phase II/III EPIC-HR (Evaluation of Protease Inhibition for Covid-19 in High-Risk Patients) trial of its novel Covid-19 oral antiviral candidate Paxlovid (nirmatrelvir [PF-07321332] tablets and ritonavir tablets). The results These results show that Paxlovid significantly reduced the… Read More
The Scitara Scientific Integration Platform (SIP) has been designed as a solution to the lab connectivity challenge that is common in the industry and reportedly allows true data mobility throughout the scientific enterprise. What is the SIP? The SIP category is a cloud native infrastructure that allows… Read More
Cytel and Pulse Infoframe have collaborated to create a solution that marks a new direction in research for rare disease. This partnership will support drug development sponsors seeking to implement real-world evidence solutions where the data generated can be used for a range of purposes, from synthetic controls and comparative effectiveness to… Read More
XORTX Therapeutics has chosen Altasciences to conduct a pharmacokinetic bridging study in support of the XRx-008 programme for autosomal dominant polycystic kidney disease (ADPKD), and XRx-101 for acute kidney injury associated with Covid-19. Context XORTX’s formulations of xanthine oxidase inhibitors are aimed at reducing uric acid levels in order… Read More
In a collaborative project funded by the Next Generation Technologies Fund, researchers from the University of Newcastle and Queensland University of Technology in Australia will investigate the human, microbial and environmental interactions that affect cognitive performance, coined the ‘cognobiome’, by analysing the gut microbiome of soldiers. The study … Read More
Mount Sinai researchers have reached a cancer research milestone and proven how cancer cells remain dormant for years after they leave a tumour and travel to other parts of the body, before awakening to create metastatic cancer. The findings According to findings reported in Nature Cancer,… Read More
Researchers from the University of Oxford have analysed the impact of the Omicron Covid-19 variant of concern on one of the immune responses generated by vaccination. The study Using blood samples from individuals who had previously received two doses of the Oxford-AstraZeneca or Pfizer-BioNTech vaccines as part… Read More
The first clinical trial in the UK to investigate whether antiviral drugs could help reduce the severity of Covid-19 is due to start, led by the University of Oxford and delivered in Wales by Cardiff University in partnership with Public Health Wales and Health and Care Research Wales. Cardiff University staff… Read More
4D Pharma, a pharmaceutical company developing Live Biotherapeutic products (LBPs), has announced new faecal microbiome analyses from the completed Phase II trial of Blautix(R) (MRx1234) as a treatment for irritable bowel syndrome with constipation (IBS-C) or with diarrhoea (IBS-D). The new data was presented in an ePoster at Gastro 2021, held from December 9-11, 2021. … Read More
PerkinElmer has announced the research use only (RUO) launch of the NEXTFLEX Variant-Seq SARS-CoV-2 Kit v2 to accelerate the detection of SARS-CoV-2 variants, which will allow laboratories to increase sequencing throughput and make reliable variant identifications. What is NEXTFLEX? Using positive SARS-CoV-2 samples, the NEXTFLEX… Read More
More than half of the world’s population is at risk from vector-borne diseases that are transmitted by insects such as mosquitoes, flies and ticks. These diseases cause more than one million deaths annually, and it is primarily people in the poorest countries who are the most vulnerable. Sophia Ktori shares insights fromTropIQ Health… Read More
News round-up by DDW’s Megan Thomas for 6-10 December In the wake of the discovery of the Omicron Covid-19 variant globally, DDW’s Megan Thomas rounds up five news stories which show the strides being made to understand and fight this variant across the drug discovery industry. … Read More
Chimeric Antigen Receptor or CAR-T cells, a new form of immunotherapy with genetically engineered immune system cells, has been approved for the treatment of multiple myeloma, a type of blood cancer. Context In a case study published in Nature Medicine, Sinai scientists reported a… Read More
Gedeon Richter has become marketing authorisation holder for Evra, a once-weekly contraception for women of fertile age, which they say is the first and only transdermal contraceptive patch licenced in the UK. Tamas Neubauer, Managing Director of UK and Ireland at Gedeon Richter, believes that the addition of a patch to their… Read More
Emmes has launched a rare disease centre, Orphan Reach, to combine its health research across the public sector and biopharmaceutical industry. DDW’s Megan Thomas spoke with Thomas Ogorka, Managing Director of Orphan Reach: Emmes’ Rare Disease Center, about its potential. MT: What will the expanded Orphan Reach centre add to what Emmes already offers? TO: First and foremost, specialised rare… Read More
Scientists at the Francis Crick Institute have uncovered biological processes key to regulating immune cells that can cause allergic reactions unless closely controlled, which they hope could help expose what goes wrong when the body develops allergies or goes into anaphylaxis. Background IgE antibodies are… Read More
